Mergers & Acquisitions
Due to our many years of practical experience and training, we can solve even complex situations and find innovative, pragmatic solutions for all participants.
Unternehmenskauf- und Verkauf
- Management Buy-Out (MBO)
- Management Buy-In (MBI)
- Fusionen & Spaltungen
Company acquisitions and sales
Local and international company sales
Target search and company acquisitions
Management Buy-Out (MBO)
Management Buy-In (MBI)
Mergers & Demergers
Valuation and financial modelling
– Valuation of Intangible Assets
– IP Valuations
– Technology Valuation
– Compound valuation
– Option Valuations
– Impairment tests
– Business plan, integrated financial planning
Fit for IPO
Reverse Merger Consulting
Succession advice and ownership strategies
We have a deep understanding of the industry and a very actively cultivated network of industry experts and exponents from all areas of the life sciences and medical technology industries, including all suppliers such as pharmaceutical service and production industries..
Other industries in our focus:
- IT, Digital & Tech
- Construction & Industrials
- Energy Sector
- Consumer & Retail
- Transport & Logistics
- Media & other services
Locally active with a global network
In addition to our wide-ranging in-house expertise, we can draw on a large regional and international network of specialists and industry experts as required (note: not only for transactions).
We are the exclusive Swiss member of the global M&A organisation AICA with M&A member firms in all important countries of the world, through which we have access to local know-how and contacts worldwide and can call on them as needed to identify and approach potential buyers or acquisition targets.
Locally, we are strongly interconnected in the Life Sciences Hub Basel/Northwestern Switzerland.
Due to our Mergers & Acquisitions and CFO service activities, we have ongoing contacts with many CFOs, CEOs / C-level management and companies from the life sciences industry in all its segments. Internationally, we maintain contacts with CFOs and organisations in other major pharmaceutical hubs.